Scarica l'app Stockscreener
3.02
0.67%
0.02
Dopo l'orario di chiusura:
3.02
Precedente Chiudi:
$3.00
Aprire:
$2.9
Volume 24 ore:
63,366
Relative Volume:
0.90
Capitalizzazione di mercato:
$28.33M
Reddito:
$2.57M
Utile/perdita netta:
$-13.54M
Rapporto P/E:
-0.5404
EPS:
-5.5882
Flusso di cassa netto:
$-23.50M
1 W Prestazione:
-9.31%
1M Prestazione:
-23.74%
6M Prestazione:
-91.92%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$2.81
$3.04
Intervallo di 1 settimana:
$2.81
$3.445
Portata 52W:
$2.81
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Nome
Tvardi Therapeutics Inc
Settore
Industria
Telefono
(713) 489-8654
Indirizzo
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Compare TVRD vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
3.02 | 28.33M | 2.57M | -13.54M | -23.50M | -5.5882 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-14 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-10-14 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-10-13 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-13 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-07-14 | Iniziato | Raymond James | Outperform |
| 2025-07-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-12 | Iniziato | Piper Sandler | Overweight |
| 2025-05-21 | Iniziato | Oppenheimer | Outperform |
| 2025-05-15 | Iniziato | BTIG Research | Buy |
| 2024-06-13 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | Downgrade | Needham | Buy → Hold |
| 2024-06-13 | Downgrade | Stifel | Buy → Hold |
| 2023-03-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-11-01 | Ripresa | Canaccord Genuity | Buy |
| 2021-08-03 | Iniziato | JP Morgan | Neutral |
| 2020-04-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-08-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-29 | Reiterato | Laidlaw | Buy |
| 2019-02-06 | Ripresa | Jefferies | Buy |
| 2019-01-15 | Iniziato | BofA/Merrill | Neutral |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Iniziato | Jefferies | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-12 | Ripresa | H.C. Wainwright | Buy |
| 2018-02-12 | Aggiornamento | Janney | Neutral → Buy |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
Mostra tutto
Tvardi Therapeutics Inc Borsa (TVRD) Ultime notizie
Tvardi Therapeutics (NASDAQ:TVRD) Cut to Sell at Wall Street Zen - Defense World
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium - Sahm
BTIG Research Reaffirms Buy Rating for Tvardi Therapeutics (NASDAQ:TVRD) - Defense World
Tvardi management heads to New York for Apr. 14 biotech symposium - Stock Titan
Barclays Lowers Price Target for Tvardi Therapeutics (TVRD) | TV - GuruFocus
Tvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development - tipranks.com
Tvardi Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Tvardi Therapeutics (TVRD) Sees Price Target Cut by Piper Sandler | TVRD Stock News - GuruFocus
Piper Sandler cuts Tvardi Therapeutics price target on trial timing - Investing.com
Tvardi Therapeutics (NASDAQ: TVRD) registers 2,084,117 resale shares; clinical updates - Stock Titan
Tvardi Therapeutics (NASDAQ: TVRD) adds auditor consent in S-1 amendment - Stock Titan
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update - Bitget
Tvardi: Q4 Earnings Snapshot - wkyc.com
Tvardi Therapeutics (NASDAQ: TVRD) outlines STAT3 trial plans - Stock Titan
Tvardi (NASDAQ: TVRD) narrows 2025 loss and eyes key 2026 trial data - Stock Titan
Tvardi lines up 2 drug readouts in 2026 with cash lasting into Q4 - Stock Titan
Tvardi Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
Tvardi Therapeutics Inc expected to post a loss of 65 cents a shareEarnings Preview - TradingView
Published on: 2026-03-31 03:05:34 - baoquankhu1.vn
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives $55.50 Consensus Price Target from Analysts - Defense World
Performance Recap: Will Tvardi Therapeutics Inc outperform during market rallies - baoquankhu1.vn
Tvardi Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | TVRD | US1407553072 - marketscreener.com
Tvardi Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | 69C | US1407553072 - marketscreener.com
Stop Loss: Is Tvardi Therapeutics Inc part of any major index2026 Short Interest & High Yield Equity Trading Tips - baoquankhu1.vn
Aug Swings: What hedge funds are buying Tvardi Therapeutics IncDollar Strength & Real-Time Sentiment Analysis - baoquankhu1.vn
Purchase/sale of business (net) of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView
Published on: 2026-03-12 05:56:22 - baoquankhu1.vn
Tvardi Therapeutics (TVRD) Stock Analysis Report | Financials & Insights - Benzinga Japan
What sentiment indicators say about Tvardi Therapeutics Inc. stockPortfolio Update Report & Free Community Consensus Stock Picks - Naître et grandir
Tvardi Therapeutics Sets Key Deadlines for 2026 Meeting - The Globe and Mail
Tvardi Therapeutics sets June 9, 2026 annual meeting; proxy and nomination deadlines announced - TradingView
[424B3] Tvardi Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Key deadlines for Tvardi Therapeutics (NASDAQ: TVRD) 2026 stockholder meeting - Stock Titan
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives $55.50 Average Price Target from Brokerages - Defense World
Growth Report: Is Tvardi Therapeutics Inc attractive for institutional investorsInsider Selling & Entry Point Confirmation Alerts - baoquankhu1.vn
Tvardi Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | 0HTC | US1407553072 - marketscreener.com
CARA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Free cash flow per share of Tvardi Therapeutics Inc. – FWB:69C - TradingView
Tvardi Therapeutics, Inc. (TVRD): Investor Outlook on the Biotech Company’s 125% Potential Upside - DirectorsTalk Interviews
Pulmonary Fibrosis Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics - Barchart
Analysts Are Bullish on These Healthcare Stocks: Inhibikase Therapeutics (IKT), MoonLake Immunotherapeutics (MLTX) - The Globe and Mail
Head-To-Head Review: Tvardi Therapeutics (NASDAQ:TVRD) vs. InflaRx (NASDAQ:IFRX) - Defense World
MSN Money - MSN
Tvardi Therapeutics, Inc. (TVRD) Stock Analysis: Exploring a Potential 140% Upside in Biotechnology - DirectorsTalk Interviews
Will Tvardi Therapeutics Inc. (69C) stock sustain uptrend momentumTrade Performance Summary & Risk Managed Investment Entry Signals - mfd.ru
Will Tvardi Therapeutics Inc. outperform during market ralliesJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - mfd.ru
What is Tvardi Therapeutics Inc.’s book value per shareJuly 2025 Macro Moves & Long-Term Growth Plans - mfd.ru
Tvardi Therapeutics, Inc. (TVRD) Stock Analysis: A Look at the 129% Potential Upside in Biotech - DirectorsTalk Interviews
Published on: 2026-02-12 23:10:23 - mfd.ru
Will Tvardi Therapeutics Inc. stock maintain dividend yield2025 Price Targets & Real-Time Stock Price Movement Reports - mfd.ru
Tvardi Therapeutics to Participate in Upcoming Investor Conferences - marketscreener.com
Tvardi Therapeutics Inc Azioni (TVRD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):